Cambridge Investment Research Advisors
NAGE

Cambridge Investment Research Advisors’s Niagen Bioscience NAGE Stock Holding History

Cambridge Investment Research Advisors’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-92,650
Closed -$338K – 3619
2024
Q3 		$338K Sell
92,650
-22,150
-19% -$69.7K ﹤0.01% 2743
2024
Q2 		$313K Sell
114,800
-8,500
-7% -$28.4K ﹤0.01% 2673
2024
Q1 		$429K Buy
123,300
+5,510
+5% +$10.2K ﹤0.01% 2404
2023
Q4 		$168K Sell
117,790
-5,128
-4% -$7.14K ﹤0.01% 2947
2023
Q3 		$179K Sell
122,918
-25,425
-17% -$39.7K ﹤0.01% 2852
2023
Q2 		$233K Sell
148,343
-46,215
-24% -$69K ﹤0.01% 2753
2023
Q1 		$298K Buy
194,558
+68,000
+54% +$121K ﹤0.01% 2498
2022
Q4 		$213K Buy
126,558
+7,000
+6% +$11.1K ﹤0.01% 2709
2022
Q3 		$147K Buy
119,558
+27,650
+30% +$44.5K ﹤0.01% 2787
2022
Q2 		$153K Sell
91,908
-5,500
-6% -$10.8K ﹤0.01% 2793
2022
Q1 		$240K Buy
97,408
+22,500
+30% +$61.5K ﹤0.01% 2737
2021
Q4 		$280K Buy
74,908
+6,050
+9% +$32.7K ﹤0.01% 2584
2021
Q3 		$432K Buy
68,858
+50
+0.1% +$412 ﹤0.01% 2158
2021
Q2 		$678K Buy
68,808
+11,175
+19% +$97.4K ﹤0.01% 1818
2021
Q1 		$538K Sell
57,633
-27,100
-32% -$215K ﹤0.01% 1851
2020
Q4 		$407K Buy
84,733
+48,750
+135% +$238K ﹤0.01% 1912
2020
Q3 		$144K Buy
+35,983
New +$174K ﹤0.01% 2325

Other funds holding NAGE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Cambridge Investment Research Advisors's NAGE Position: Q4 2024 in Review

Cambridge Investment Research Advisors sold out of Niagen Bioscience (NAGE) in Q4 2024, closing a stake of 92,650 shares — an estimated $338K sold.

Cambridge Investment Research Advisors first reported a position in NAGE in Q3 2020 and held it in 17 quarters. The position peaked at $678K in Q2 2021. 123 funds tracked by Wall St. Rank hold NAGE as of Q4 2024.

  • Cambridge Investment Research Advisors reported no remaining Niagen Bioscience position as of Q4 2024 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 92,650 Niagen Bioscience shares in Q4 2024, an estimated $338K.
  • Cambridge Investment Research Advisors first reported a position in Niagen Bioscience in Q3 2020 and held it in 17 quarters.
  • Cambridge Investment Research Advisors's Niagen Bioscience position peaked at $678K in Q2 2021.
  • 123 funds tracked by Wall St. Rank held Niagen Bioscience as of Q4 2024.

Based on Cambridge Investment Research Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.